GlassScriptPhysician profile
Robert G Piccinini
NPI 1457443517
$11,829.61
in general payments reported to CMS, 2019-2025
40 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,469 · 2020: $1,079 · 2021: $2,394 · 2022: $1,622 · 2023: $2,265 · 2024: $1,442 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,266.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,628.56 | 2019-2025 | Equetro, Raldesy, Equetro |
| Otsuka America Pharmaceutical, INC. | $1,168.26 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Lundbeck LLC | $1,161.79 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $844.32 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $798.79 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $682.50 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $620.73 | 2021-2025 | |
| Corium, LLC | $610.40 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $577.88 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $491.98 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $470.02 | 2021-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $391.21 | 2019-2022 | |
| Allergan, INC. | $314.00 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $254.52 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $205.92 | 2021-2025 | Qelbree, Qelbree |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Piccinini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.